Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern.

"Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest."

"We thank technicians Isolde Enz, Mariam Ghorbani, Ruth Mader, Bettina Sartori, and Tanja Triendl (University Hospital of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria), as well as Gabriel Diem (Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck) for their valuable help and support regarding this study. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA (NIBSC 19/304) was obtained from the National Institute for Biological Standards and Control, United Kingdom. The following reagents were deposited by the US Centers for Disease Control and Prevention and obtained through BEI Resources, National Institute of Allergy and Infectious Diseases, US National Institutes of Health: SARS-related coronavirus 2, isolate USA-WA1/2020 NR-52281; SARS-related coronavirus 2, isolate hCoV-19/England/204820464/2020, NR-54000, contributed by Bassam Hallis; and SARS-related coronavirus 2, isolate hCoV-19/South Africa/KRISP-K005325/2020, NR-54009, contributed by Alex Sigal and Tulio de Oliveira. The authors were supported by the 10.13039/501100002428Austrian Science Fund (FWF; P34070-B to W.P. and P33510-B to D.W.), the Anniversary Fund of the Austrian National Bank (OeNB; P17614 to W.P., P17633 to D.W.), and the state of Tyrol (70454 to W.P.)."